中晚期肝癌双重化疗术的应用研究  

Study on double chemotherapy for advanced Primary hepatic carcinoma

作　　者：徐昌青[1] 刘元水[1] 李荔[1] 张钦[1] 沙建梓[1] 刘倩[1] 李士玉[1] 

机构地区：[1]山东省千佛山医院消化内科超声诊断科,济南市250014

出　　处：《胃肠病学和肝病学杂志》1999年第1期66-68,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：探讨双重化疗术在中晚期肝癌的应用价值及门静脉导管保留术的实用价值；方法１５例中晚期肝癌患者采用经肝动脉的化疗药物灌注术和经皮经肝门静脉穿刺、门静脉化疗药物灌注术，其中１２例经矢状部穿刺行门静脉导管保留术，籍以反复进行化疗药物灌注，共行肝动脉化疗２２次，门静脉化疗４３次，导管保留时间自１５－３７天不等，平均为２４．２±７．６天。结果双重化疗使患者病情明显改善，生存期显著延长，疼痛显著减轻，ＡＦＰ下降，门脉压力下降，单叶肿瘤化疗效果显著优于双叶肿瘤，部份患者可争取手术切除。结论双重化疗是治疗中、晚期肝癌的有效办法，门静脉导管保留术是简便易行、临床实用的技术。Aims The study was set up to evaluate the effect of double chemotherapy and portal reserve catheter(PRC) in the patients with advanced stage of PHC. Methods 15 cases of advanced stage of PHC accepted the doublechemotherapy, including transhepatic axtery chemotherapy and transcutaneous intrahepatic portal vein chemotherapy (TAC andTVC). of those 12 cases accepted puncture at transmittal section of portal vein to use TVC repeatedly. 22 times of TAC and43 times of TVC were tallen. Catheter reserved from 15 ~ 37 days, mean 24.2 t 7. 6 days. Results The double chemotherapy can improve the Patient's conditions, prolong survival period and alleviate the patient's suffering. The scheme decreaseAFP level and portal venous pressure. The curative effect on the patients with monolobate tumor is better than those wilh bilObate ttnnor, and part of the patients got a chance of excision. Conclusion Double chemotherapy is an effective scheme intreatment of patients with advanced stage of PHC and PRC is a simple, Practical method and easy to opelate.

关 键 词：中晚期 肝癌 双重化 门静脉导管保留 

分 类 号：R735.705[医药卫生—肿瘤] R730.53[医药卫生—临床医学]